These results may have exciting implications in combination with the recently demonstrated efficacy of ATP-competitive HSP90 inhibitors in blocking KSHV latent cycle in vitro and in a xenograft KSHV tumour model [41]. This evidence concerns the gene HSP90AA1 and neoplasm.